And what it will not. Expert Opin Pharmacother 2012, 13(11):1599613. 28. Voruganti L, Awad G: Individual evaluation of transitions in treatment (PETIT) a scale to measure subjective elements of antipsychotic drug therapy in schizophrenia. Schizophren Res 2002, 56:376. 29. Ware JE, Kosinski M, Keller SD: A 12-item short-form overall health survey: construction of scales and preliminary tests of reliability and validity. Healthcare Care 1996, 34(three):22033. 30. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR: The cost of relapse plus the predictors of relapse in the therapy of schizophrenia. BMC Psychiatry 2010, 10:two. 31. Stahl SM: From antipsychotic agents. In Antipsychotics and Mood Stabilizers: Stahl’s Critical Psychopharmacology. 3rd edition. New York: Cambridge University Press; 2008:18586. 32. Awad AG: Subjective tolerability of antipsychotic medicines and the emerging science of subjective tolerability disorders. Expert Rev Pharmacoeconomics Outcomes Res 2010, 10(1):1. 33. Voruganti L, Cortese L, Oyewumi L, Cernovsky A, Zirul S, Awad A: Comparative evaluation of traditional and novel antipsychotic drugs with reference to their subjective tolerability side-effect profile and effect on CB1 Agonist supplier high-quality of life. Schizophr Res 2000, 43(two):13545. 34. Papaioannou D, Brazier J, Parry G: How valid and responsive are generic overall health status measures, including EQ-5D and SF-36, in schizophrenia A systematic assessment. Worth Health 2011, 14(6):9070.35. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meuliend D: Switching from other antipsychotics to once-daily extended release quetiapine fumarate in individuals with schizophrenia. Curr Med Res Opin 2008, 24(1):212. 36. Kim S-W, Shin I-S, Kim J-M, Lee J-H, Lee Y-H, Yang S-J, Yoon J-S: Effectiveness of switching to aripiprazole from atypical antipsychotics in sufferers with schizophrenia. Clin Neuropharmacol 2009, 32(five):24349. 37. Weiden PJ, Simpson GM, Potkin SG, O’Sullivan RL: Effectiveness of switching to ziprasidone for steady but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003, 64(five):58088. 38. Kim S-W, Shin I-S, Kim J-M, Lee S-H, Lee Y-H, Yang S-J, Yoon J-S: Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive functioning in patients with schizophrenia. Hum Psychopharmacol Clin Exp 2009, 24:56573. 39. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ: Clinical and economic ramifications of switching antipsychotics within the treatment of schizophrenia. BMC Psych 2009, 9:54. 40. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG, Aripiprazole study group: Switching sufferers to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol (Berl) 2003, 166(four):391. 41. Su J, Barr AM, Bcl-2 Inhibitor review Procyshyn RM: Adverse events associated with switching from traditional antipsychotic drugs or risperidone to olanzapine. J Psychiatry Neurosci 2012, 37(1):E1 two.doi:10.1186/1471-244X-14-53 Cite this short article as: Awad et al.: Health-related good quality of life amongst individuals treated with lurasidone: outcomes from a switch trial in sufferers with schizophrenia. BMC Psychiatry 2014 14:53.Submit your next manuscript to BioMed Central and take full benefit of:Handy on line submission Thorough peer evaluation No space constraints or colour figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Analysis which can be freely readily available for redistributionSubmit you.